Component
Clinical outcomes with different treatment timing in PSAT1 deficiency
Context-specific entity; species, compartment and exposure are stated on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Two siblings received serine plus glycine at different ages: the index child treated from 11 weeks died at seven months, whereas the sibling treated from birth had a normal reported outcome at age three.
Experimental context and source evidence
- availability_state
- machinery_impairment Imported condition classification; unverified.
- evidence_access
- Primary abstract
- experimental_model
- Two siblings; reported regimens included serine 500 mg/kg/day and glycine 200 mg/kg/day.
- limitations
- Case comparison is not randomized proof, a universal rescue, or a dosing recommendation.
- nutrient_topic
- L-Serine collection; species, compartment, exposure, co-substrates and manipulation remain explicit. · L-Serine
- plain_language
- Timing may matter when early development depends on local amino-acid supply.
- primary_references
- Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17436247/ · DOI 10.1086/517888
- trigger_kind
- machinery_impairment Imported condition classification; unverified.
L-Serine: synthesis, one-carbon metabolism, lipids and cross-nutrient mechanisms (2026-09-19) · lines 110–116
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Two siblings; reported regimens included serine 500 mg/kg/day and glycine 200 mg/kg/day. · source_derived_draft · unverified_draft
## l-serine-psat-early-treatment Timing may matter when early development depends on local amino-acid supply. Two siblings received serine plus glycine at different ages: the index child treated from 11 weeks died at seven months, whereas the sibling treated from birth had a normal reported outcome at age three. Model: Two siblings; reported regimens included serine 500 mg/kg/day and glycine 200 mg/kg/day. Limitations: Case comparison is not randomized proof, a universal rescue, or a dosing recommendation. Evidence access: Primary abstract Phosphoserine aminotransferase deficiency: a novel disorder of the serine biosynthesis pathway. · 2007 · https://pubmed.ncbi.nlm.nih.gov/17436247/ · DOI 10.1086/517888
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.